Sergio Y Gómez1, Raquel E Ocazionez. 1. Centro de Investigaciones en Enfermedades Tropicales, Universidad Industrial de Santander, Bucaramanga, Colombia. sergioyebrailgm@yahoo.com
Abstract
OBJECTIVE: Determining the frequency of yellow fever seroprotective antibody neutralising titres (YF-NT >or=1:10) in Colombians vaccinated with the 17 D virus and ascertaining the extent to which YF virus can be neutralised by dengue antibodies. MATERIALS AND METHODS: Serum samples were taken from 100 subjects who showed their vaccination record and from 116 residents in municipalities (Norte de Santander) affected by a wild YF outbreak in 2002-2003 who were reported to have been YF vaccinated. Sera from individuals with (n=61) and without (n=16) dengue antibodies who had never been YF vaccinated were included. All the sera were tested by 75 % YF plaque-reduction neutralization test. RESULTS: YF-NT titres >or=1:10 were founded in 90 % of subjects with vaccination recorded with minors variations in relation to age. In contrast, there was correlation between decrease of seroprotective YF-NT titres frequency and increase of immunization time (r=0.95; p=0.04). In residents in YF endemic area, YF-NT titres >or= 1.10 were founded in 92,6 % adults and 69 % children. YF 17 D virus was neutralized (52-100 %) by dengue sera more efficiently than non-dengue immune sera (p<0.001). CONCLUSIONS: Individuals immunised with YF vaccine 17 D could not be protected against YF: up to 31% children and 10 % adults. Dengue antibodies inhibited YF virus and its significance in terms of YF protection must be investigated.
OBJECTIVE: Determining the frequency of yellow fever seroprotective antibody neutralising titres (YF-NT >or=1:10) in Colombians vaccinated with the 17 D virus and ascertaining the extent to which YF virus can be neutralised by dengue antibodies. MATERIALS AND METHODS: Serum samples were taken from 100 subjects who showed their vaccination record and from 116 residents in municipalities (Norte de Santander) affected by a wild YF outbreak in 2002-2003 who were reported to have been YF vaccinated. Sera from individuals with (n=61) and without (n=16) dengue antibodies who had never been YF vaccinated were included. All the sera were tested by 75 % YF plaque-reduction neutralization test. RESULTS:YF-NT titres >or=1:10 were founded in 90 % of subjects with vaccination recorded with minors variations in relation to age. In contrast, there was correlation between decrease of seroprotective YF-NT titres frequency and increase of immunization time (r=0.95; p=0.04). In residents in YF endemic area, YF-NT titres >or= 1.10 were founded in 92,6 % adults and 69 % children. YF17 D virus was neutralized (52-100 %) by dengue sera more efficiently than non-dengue immune sera (p<0.001). CONCLUSIONS: Individuals immunised with YF vaccine 17 D could not be protected against YF: up to 31% children and 10 % adults. Dengue antibodies inhibited YF virus and its significance in terms of YF protection must be investigated.
Authors: Ricardo O Izurieta; Maurizio Macaluso; Douglas M Watts; Robert B Tesh; Bolivar Guerra; Ligia M Cruz; Sagar Galwankar; Sten H Vermund Journal: J Glob Infect Dis Date: 2009-07
Authors: Nicole P Lindsey; Kalanthe A Horiuchi; Corey Fulton; Amanda J Panella; Olga I Kosoy; Jason O Velez; Elizabeth R Krow-Lucal; Marc Fischer; J Erin Staples Journal: J Travel Med Date: 2018-01-01 Impact factor: 8.490
Authors: Andréa Barbosa de Melo; Maria da Paz C da Silva; Maria Cecília F Magalhães; Laura Helena Vega Gonzales Gil; Eduardo M Freese de Carvalho; Ulisses M Braga-Neto; Giovani Rota Bertani; Ernesto T A Marques; Marli Tenório Cordeiro Journal: Am J Trop Med Hyg Date: 2011-10 Impact factor: 2.345
Authors: Bettie W Kareko; Brian L Booty; Chad D Nix; Zoe L Lyski; Mark K Slifka; Ian J Amanna; William B Messer Journal: J Infect Dis Date: 2020-06-11 Impact factor: 7.759
Authors: Rosanne W Wieten; Emile F F Jonker; Ester M M van Leeuwen; Ester B M Remmerswaal; Ineke J M Ten Berge; Adriëtte W de Visser; Perry J J van Genderen; Abraham Goorhuis; Leo G Visser; Martin P Grobusch; Godelieve J de Bree Journal: PLoS One Date: 2016-03-15 Impact factor: 3.240